Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMVISION-1: Brodalumab in Psoriatic Arthritis
2013-003554-25Phase 3Terminated
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brodalumab in psoriatic arthritis (PsA) (3 arms), sponsored by Amgen. Primary endpoint: ACR20 response at week 16. Started Nov 2013; status: terminated.
02
Drugs
brodalumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2013-003554-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003554-25.